Amid a huge furore over unsafe implanted medical devices the US FDA has released new proposals that are cautious to the point of toothlessness – and wouldn’t affect most…
Technology developed by GTX Medical has shown astonishing results in paralysed patients. Monetising it might be an even more impressive achievement.
BTG’s string-of-beads tempts Boston Scientific to shell out £3.3bn ($4.2bn) for the UK company.
Mainstay Medical still hopes for US approval of its Reactiv8 device for chronic back pain despite trial failure.
The world’s first non-implanted vagus nerve stimulator is becoming established as a therapy for headache and migraine. But a move into autoimmune conditions will require…
An adcom for Impulse Dynamics’ heart muscle stimulator is approaching, and the group will want to avoid a nasty shock.
The phase III failure of one of Bone Therapeutics’ cell therapies puts its other one under greater pressure than ever.
Illumina’s $1.2bn buy of Pacific Biosciences raises questions about why it shunned another long-read sequencing player, Oxford Nanopore Technologies.
The Swiss group has succeeded with its internally developed diagnostics, but buying in innovation has served Becton Dickinson well.